
PainReform Ltd. EBITDA | PRFX
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA PainReform Ltd.
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.11 M | -14.7 M | -9.57 M | -8.85 M | -7.2 M | -1.67 M | -688 K | -500 K | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -500 K | -14.7 M | -6.03 M |
Quarterly EBITDA PainReform Ltd.
| 2025-Q4 | 2025-Q2 | 2024-Q4 | 2024-Q2 | 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.11 M | -2.36 M | -14.7 M | -12.9 M | -9.57 M | -4.66 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -2.36 M | -14.7 M | -8.21 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Biotechnology industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Bristol-Myers Squibb Company
BMY
|
4.01 B | $ 58.74 | 0.69 % | $ 119 B | ||
|
Eiger BioPharmaceuticals
EIGR
|
-71.5 M | - | -9.21 % | $ 2.55 M | ||
|
IGM Biosciences
IGMS
|
-199 M | - | - | $ 76.9 M | ||
|
Merrimack Pharmaceuticals
MACK
|
-2.04 M | - | - | $ 216 M | ||
|
Rubius Therapeutics
RUBY
|
-172 M | - | -33.55 % | $ 7.81 M | ||
|
Mirati Therapeutics
MRTX
|
-757 M | - | - | $ 3.3 B | ||
|
InVivo Therapeutics Holdings Corp.
NVIV
|
-10.6 M | - | -37.48 % | $ 476 K | ||
|
Bellicum Pharmaceuticals
BLCM
|
-27 M | - | -9.72 % | $ 5.89 M | ||
|
Orchard Therapeutics plc
ORTX
|
-124 M | - | 1.02 % | $ 90.8 M | ||
|
La Jolla Pharmaceutical Company
LJPC
|
21.9 M | - | - | $ 154 M | ||
|
Oyster Point Pharma
OYST
|
-96.5 M | - | - | $ 300 M | ||
|
Intercept Pharmaceuticals
ICPT
|
-18.3 M | - | - | $ 643 M | ||
|
Chinook Therapeutics
KDNY
|
-182 M | - | - | $ 2.6 B | ||
|
Syros Pharmaceuticals
SYRS
|
-127 M | - | -8.44 % | $ 3.4 M | ||
|
NanoViricides
NNVC
|
-7.79 M | $ 1.15 | -2.54 % | $ 23.2 M | ||
|
GT Biopharma
GTBP
|
-12.4 M | $ 2.93 | -7.86 % | $ 16.2 M | ||
|
Zymeworks
ZYME
|
-212 M | $ 26.41 | -1.68 % | $ 1.36 B | ||
|
Aldeyra Therapeutics
ALDX
|
-35 M | $ 0.84 | 16.41 % | $ 50.4 M | ||
|
Citius Pharmaceuticals
CTXR
|
-38.5 M | $ 0.51 | 1.61 % | $ 5.64 M | ||
|
Cytokinetics, Incorporated
CYTK
|
-602 M | $ 50.7 | -1.48 % | $ 6.09 M | ||
|
DBV Technologies S.A.
DBVT
|
-144 M | $ 9.03 | -4.14 % | $ 1.26 B | ||
|
Precision BioSciences
DTIL
|
-50.7 M | $ 7.37 | 6.66 % | $ 94.5 M | ||
|
Exelixis
EXEL
|
901 M | $ 64.59 | -1.88 % | $ 17.5 B | ||
|
Fennec Pharmaceuticals
FENC
|
-6.28 M | $ 13.09 | -2.68 % | $ 374 M | ||
|
Cardiff Oncology
CRDF
|
-48.6 M | $ 0.85 | -4.67 % | $ 56.8 M | ||
|
BioNTech SE
BNTX
|
-1.4 B | $ 80.87 | -0.63 % | $ 19.5 B | ||
|
Alkermes plc
ALKS
|
281 M | $ 44.89 | -2.79 % | $ 7.39 B | ||
|
ANI Pharmaceuticals
ANIP
|
203 M | $ 68.6 | -0.77 % | $ 1.38 B | ||
|
AIM ImmunoTech
AIM
|
-11.6 M | $ 0.11 | -7.75 % | $ 178 K | ||
|
AC Immune SA
ACIU
|
-69.3 M | $ 1.98 | -7.28 % | $ 199 M | ||
|
Atara Biotherapeutics
ATRA
|
38 M | $ 6.51 | 2.6 % | $ 81.7 M | ||
|
Allogene Therapeutics
ALLO
|
-197 M | $ 0.63 | -5.62 % | $ 139 M | ||
|
Altimmune
ALT
|
-94.4 M | $ 1.33 | -6.03 % | $ 117 M | ||
|
AnaptysBio
ANAB
|
32.3 M | $ 46.65 | -1.58 % | $ 1.35 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.18 M | - | -1.52 % | $ 24.7 M | ||
|
Ascendis Pharma A/S
ASND
|
-136 M | $ 252.39 | -1.39 % | $ 15.3 B | ||
|
Arcturus Therapeutics Holdings
ARCT
|
-73.2 M | $ 7.42 | -2.37 % | $ 203 M | ||
|
Aurinia Pharmaceuticals
AUPH
|
52.7 M | $ 14.7 | -1.28 % | $ 1.98 B | ||
|
Autolus Therapeutics plc
AUTL
|
-262 M | $ 0.91 | -6.96 % | $ 242 M | ||
|
Atea Pharmaceuticals
AVIR
|
-180 M | $ 3.97 | 0.89 % | $ 324 M | ||
|
Axsome Therapeutics
AXSM
|
-166 M | $ 129.32 | -4.69 % | $ 6.43 B | ||
|
BridgeBio Pharma
BBIO
|
-518 M | $ 75.96 | -2.84 % | $ 14.5 B | ||
|
BioCryst Pharmaceuticals
BCRX
|
342 M | $ 7.23 | -1.3 % | $ 1.52 B | ||
|
Bicycle Therapeutics plc
BCYC
|
-241 M | $ 2.89 | -5.25 % | $ 200 M | ||
|
Benitec Biopharma
BNTC
|
-51.1 M | $ 7.95 | -2.4 % | $ 370 M | ||
|
DiaMedica Therapeutics
DMAC
|
-34.4 M | $ 8.24 | 2.74 % | $ 387 M | ||
|
Insmed Incorporated
INSM
|
-1.24 B | $ 141.06 | -2.35 % | $ 28.1 B | ||
|
Iovance Biotherapeutics
IOVA
|
-390 M | $ 6.9 | -5.61 % | $ 2.47 M | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
-10.6 M | $ 4.64 | 17.17 % | $ 56.6 M | ||
|
InMed Pharmaceuticals
INM
|
205 K | $ 15.56 | 13.57 % | $ 64.8 M |